Sutro Biopharma Stock Price, News & Analysis

Sutro Biopharma, Inc. (NASDAQ: STRO) announced new nonclinical data on its folate receptor alpha-targeting antibody-drug conjugate STRO-002 at the AACR Annual Meeting 2022. Currently in Phase 1 clinical trials for ovarian and endometrial cancers, STRO-002 demonstrated significant anti-tumor immunity through in vitro studies inducing immunogenic cell death. In vivo studies revealed enhanced efficacy in combination with checkpoint inhibitors and anti-VEGF antibodies. The data highlights STRO-002's potential for targeting FolRα-expressing tumors and its promising role in non-small cell lung cancer.

Sutro Biopharma (NASDAQ: STRO) announced that CEO Bill Newell will present at the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 3:00 p.m. ET. The presentation will be available on the company's website. Sutro focuses on next-generation cancer therapeutics through protein engineering. It has developed STRO-001 and STRO-002, targeting advanced B-cell malignancies and ovarian/endometrial cancers, respectively. Both candidates have received FDA designations to expedite development. Sutro is committed to transforming cancer treatment by creating medicines for unmet medical needs.

Sutro Biopharma (NASDAQ: STRO) announced advancements in its novel immunostimulatory antibody-drug conjugate (iADC) modality at the 12th Annual World ADC conference held in London from March 29 to April 1, 2022. This innovative approach uses a dual mechanism to target tumors, leveraging a cytotoxic warhead and a toll-like receptor (TLR) agonist to activate the immune system. Presentations featured data on STRO-002, aimed at treating ovarian and endometrial cancers, which has received Fast Track designation from the FDA. Sutro aims to develop therapies that address unmet needs in oncology.

Sutro Biopharma (NASDAQ: STRO) announced that CEO Bill Newell will participate in the Ovarian Cancer Panel at the Cowen 42nd Annual Healthcare Conference on March 9, 2022, at 12:50 p.m. ET. A live webcast can be accessed on the company's website, with a replay available for 30 days. Sutro is focused on cancer therapeutics through its platforms XpressCF® and XpressCF+™, which led to drug candidates like STRO-001 and STRO-002, both in clinical trials with FDA designations. Sutro is dedicated to improving cancer treatment for patients.

Sutro Biopharma (STRO) reported a strong performance for 2021, with revenue increasing to $61.9 million from $42.7 million in 2020, driven by collaborations with Merck, BMS, and EMD Serono. The company is advancing its lead candidate, STRO-002, which targets ovarian cancer, completing its Phase 1 trial enrollment and planning a registrational path forward. However, operating expenses rose to $160.4 million, up from $113.8 million, partly due to stock-based compensation. Sutro's cash reserves stood at $229.5 million, providing runway into late 2023.

Sutro Biopharma (NASDAQ: STRO), a clinical-stage company based in South San Francisco, announced that CEO Bill Newell will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 11:15 a.m. ET. The live presentation will be available via webcast on the company's website. Sutro focuses on advanced oncology therapeutics, using its XpressCF® platform to develop candidates like STRO-001 and STRO-002, currently in clinical trials for B-cell malignancies and ovarian cancer, respectively.

Sutro Biopharma (NASDAQ: STRO) announced interim results from its Phase 1 study of STRO-002, a folate receptor alpha-targeting ADC for advanced ovarian cancer. The study, involving 44 patients with extensive prior treatments, reported an overall response rate (ORR) of 33%. Notably, patients starting at a 5.2 mg/kg dose level exhibited a 47% ORR. Encouraging safety signals included no new complications. Sutro plans to advance STRO-002 into further clinical phases, leveraging its Fast Track designation.

Sutro Biopharma (NASDAQ: STRO) has entered an exclusive license agreement with Tasly Biopharmaceuticals for the development and commercialization of STRO-002 in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan. Sutro will receive an upfront payment of $40 million and could earn up to $345 million in milestone payments. STRO-002 is currently in clinical trials for ovarian and endometrial cancers. Sutro retains rights outside of Greater China and will receive royalties based on STRO-002's net sales.

Sutro Biopharma (STRO) announced a KOL virtual event on Jan. 5, 2022, to share interim data from the Phase 1 study of STRO-002, an antibody-drug conjugate for advanced ovarian cancer. The trial, which enrolled 44 patients by Nov. 2021, aims to assess the efficacy, safety, and tolerability of STRO-002 in patients who have undergone multiple prior therapies. The event will feature presentations from Sutro management and Dr. R. Wendel Naumann from the Levine Cancer Institute.